Vanguard Capital Management
INKT icon

Vanguard Capital Management’s MiNK Therapeutics INKT Stock Holding History

Vanguard Capital Management’s Portfolio INKT Stock Details INKT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$803K Buy
68,660
+9,296
+16% +$108K ﹤0.01% 3634
2026
Q1 		$625K Buy
+59,364
New +$662K ﹤0.01% 3638

Other funds holding INKT

DnB Asset Management
DnB Asset Management Oslo, Norway $35.7B AUM 27.58% 1-Year Est. Return
LF
Longbow Finance Lutry, Switzerland $782M AUM 48.76% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
SPIA
Steward Partners Investment Advisory New York $19.6B AUM 29.84% 1-Year Est. Return
US Bancorp
US Bancorp Minneapolis, Minnesota $91.6B AUM 29.2% 1-Year Est. Return
PP
Paladin Partners Hartland, Wisconsin $151M AUM

Vanguard Capital Management's INKT Position: Q2 2026 in Review

Vanguard Capital Management increased its MiNK Therapeutics (INKT) stake by 16% in Q2 2026, buying an estimated $108K and bringing the position to 68,660 shares worth $803K. The position accounts for ﹤0.01% of the portfolio, ranked #3634.

Vanguard Capital Management first reported a position in INKT in Q1 2026 and has held it in 2 quarters since. 28 funds tracked by Wall St. Rank hold INKT as of Q2 2026.

  • Vanguard Capital Management held 68,660 shares of MiNK Therapeutics worth $803K as of Q2 2026.
  • Vanguard Capital Management bought 9,296 MiNK Therapeutics shares in Q2 2026, an estimated $108K.
  • MiNK Therapeutics made up ﹤0.01% of Vanguard Capital Management's portfolio in Q2 2026, its #3634 holding.
  • Vanguard Capital Management first reported a position in MiNK Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 28 funds tracked by Wall St. Rank held MiNK Therapeutics as of Q2 2026.

Based on Vanguard Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.